<SEC-DOCUMENT>0001048477-23-000016.txt : 20230426
<SEC-HEADER>0001048477-23-000016.hdr.sgml : 20230426
<ACCEPTANCE-DATETIME>20230426160724
ACCESSION NUMBER:		0001048477-23-000016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230426
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230426
DATE AS OF CHANGE:		20230426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		23849750

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bmrn-20230426.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:0e43f1f0-b255-4e25-b4ed-35f17c544e91,g:b0ec60c5-ba62-45dd-8184-f7166a29b045,d:89a05f8ab2f54fcc87f8859270bba7b1--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bmrn-20230426</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV80L2ZyYWc6MDhkYjVlZmQ2NDc2NDRlMGI0ZjM2YjcxNWY3MWQ4N2YvdGFibGU6NTgwZTNlYzlkODE4NGU2YjliZjc5OGZjY2EyN2JjODcvdGFibGVyYW5nZTo1ODBlM2VjOWQ4MTg0ZTZiOWJmNzk4ZmNjYTI3YmM4N18yLTEtMS0xLTExMzAyMQ_78444f19-7370-4eed-9b61-b3a1b0d98130">0001048477</ix:nonNumeric><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV80L2ZyYWc6MDhkYjVlZmQ2NDc2NDRlMGI0ZjM2YjcxNWY3MWQ4N2YvdGFibGU6NTgwZTNlYzlkODE4NGU2YjliZjc5OGZjY2EyN2JjODcvdGFibGVyYW5nZTo1ODBlM2VjOWQ4MTg0ZTZiOWJmNzk4ZmNjYTI3YmM4N181LTEtMS0xLTExMzAyMQ_b8997d0d-1fea-4ab2-ba57-5b4b21a5d104">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bmrn-20230426.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id433381570bf46f4910d270a56672296_D20230426-20230426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i89a05f8ab2f54fcc87f8859270bba7b1_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV84NA_be8c2567-094e-47b1-92c6-b927a97bd549">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8yMjU_b9edf739-eea2-4658-9de8-3f9807190f9b">April&#160;26, 2023</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNjYy_1cc06ebe-5312-4524-bf2d-daa428507c78">BioMarin Pharmaceutical Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18wLTAtMS0xLTExMzAyMQ_3431473b-e2f9-42c1-a390-0628240c3e4c">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18wLTEtMS0xLTExMzAyMQ_907b1d68-d6d4-4789-8369-d2f7110ef2be">000-26727</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18wLTMtMS0xLTExMzAyMQ_98ffb150-e3b4-4c95-8d28-5c0f3aeb7837">68-0397820</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTAtMS0xLTExMzAyMQ_a08e4441-962b-49d0-934a-85a810e44724">770 Lindaro Street</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTEtMS0xLTExMzAyMQ_2d06f65f-1af1-4475-b695-05afbed5e916">San Rafael</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTItMS0xLTExMzAyMQ_99b98106-5ab5-4bdc-9ce3-fd1f61bdedb3">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTMtMS0xLTExMzAyMQ_b315f251-c097-4d5b-83b9-4ab44b69bc98">94901</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNjYz_78973779-9a25-4f25-b3fb-bdc4d0326bc5">415</ix:nonNumeric>) <ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNjYw_e9871956-67f0-4de8-bfdf-6e536b2a156b">505-6700</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not Applicable </span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV82NzY_98bdd711-3a0d-407b-8231-5cc67ad22caa">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV83NjY_4ff025f4-76a1-489e-95a0-a90e4c6d1a9c">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV84NTg_e411a04a-d21b-46ff-9cd3-151846db89c3">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV85NjY_5d2ba802-599a-48d4-a5d3-7e7a832acfaa">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:30.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6ZGQ5OWRkNTYzNWNhNDIxYWFhNzI0MDdiNmI2MjYxY2MvdGFibGVyYW5nZTpkZDk5ZGQ1NjM1Y2E0MjFhYWE3MjQwN2I2YjYyNjFjY18xLTAtMS0xLTExMzAyMQ_ddf9b64a-72b0-4230-8303-43f0e63bfc64">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6ZGQ5OWRkNTYzNWNhNDIxYWFhNzI0MDdiNmI2MjYxY2MvdGFibGVyYW5nZTpkZDk5ZGQ1NjM1Y2E0MjFhYWE3MjQwN2I2YjYyNjFjY18xLTItMS0xLTExMzAyMQ_2b4d57ad-4518-459c-a10f-4a3069e167cd">BMRN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6ZGQ5OWRkNTYzNWNhNDIxYWFhNzI0MDdiNmI2MjYxY2MvdGFibGVyYW5nZTpkZDk5ZGQ1NjM1Y2E0MjFhYWE3MjQwN2I2YjYyNjFjY18xLTQtMS0xLTExMzAyMQ_48a1cd54-8fa2-4a6b-87a6-651ffc375e7e">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNDAx_154eb444-bb5a-4a51-bb74-aa6f428ceb32">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89a05f8ab2f54fcc87f8859270bba7b1_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April&#160;26, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March&#160;31, 2023. The Company&#8217;s press release issued on April&#160;26, 2023 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89a05f8ab2f54fcc87f8859270bba7b1_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:14.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="earningsrelease-26apr23ex9.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Press Release of the Company dated April&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89a05f8ab2f54fcc87f8859270bba7b1_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:47.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc., <br/>a Delaware corporation</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date: April&#160;26, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ G. Eric Davis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">G. Eric Davis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Executive Vice President, Chief Legal Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>earningsrelease-26apr23ex9.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibaa44edcfad841d6ba0d8cda14256205_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><img alt="bmrnlogoa01.jpg" src="bmrnlogoa01.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:176px"></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:48.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Contact&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investors&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Media&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Traci McCarty</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Marni Kottle</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(415) 455-7558</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(650) 374-2803</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of  Total Revenues </font></div><div style="margin-bottom:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Growth of VOXZOGO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance </font></div><div style="margin-bottom:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Full-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed&#59; ROCTAVIAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net Product Revenue Guidance Adjusted for Full-year 2023</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In Germany, Growing Pipeline of People with Severe Hemophilia A Getting Tested for ROCTAVIAN Treatment Eligibility&#59; ROCTAVIAN U.S. Launch Preparations Underway Ahead of June 30 Prescription Drug User Fee Act (PDUFA) Target Action Date</font></div><div><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">596.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">519.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Enzyme Product Revenues </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">448.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">426.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net Product Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net Product Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOXZOGO Net Product Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net Product Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KUVAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net Product Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net Product Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net Product Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Net Income </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Income </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Diluted Earnings per Share (EPS)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.63&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Diluted EPS </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents &#38; investments</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,625.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Enzyme-based products include ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, and VIMIZIM. </font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;GAAP Net income in the first quarter of 2022 included a $89.0 million net gain, net of taxes related to the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the U.S. Food and Drug Administration (FDA) in connection with U.S. approval of VOXZOGO. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;Non-GAAP Income is defined by the Company as reported GAAP Net Income&#47;Loss, excluding amortization expense, stock-based compensation expense, contingent consideration, and, in certain periods, certain other specified items. The Company also includes a Non-GAAP adjustment for the estimated income tax effect of reconciling items. Refer to Non-GAAP Information beginning on page </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibaa44edcfad841d6ba0d8cda14256205_13" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of this press release for a complete discussion of the Company&#8217;s Non-GAAP financial information and reconciliations to the comparable information reported under U.S. GAAP.</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) &#160;&#160;&#160;&#160;Non-GAAP Diluted EPS is defined by the Company as Non-GAAP Income divided by Non-GAAP diluted shares outstanding.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SAN RAFAEL, Calif., April&#160;26, 2023 &#8211; BioMarin Pharmaceutical Inc. (NASDAQ&#58; BMRN) (BioMarin or the Company) today announced financial results for the first quarter ended March&#160;31, 2023. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We begin 2023 by delivering double-digit revenue growth in the first quarter driven by continued strong, global uptake of VOXZOGO, solid growth of our enzyme business and ongoing focus on operational excellence. In addition to record-breaking revenue, we were also pleased with continued profitability in the quarter,&#8221; said Jean-Jacques Bienaim&#233;, Chairman and Chief Executive Officer of BioMarin. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Bienaim&#233; continued, &#8220;During the quarter, with respect to ROCTAVIAN, we were pleased with progress made in Germany with physicians and those with severe hemophilia A interested in treatment. Specifically, we were encouraged by feedback from German hematologists interested in ROCTAVIAN, as well as the number of people pursuing antibody testing to determine their eligibility for treatment. To further support the hemophilia A community in Germany, today we announce the decision to work directly with the primary, public health insurer to facilitate access to ROCTAVIAN, rather than pursue additional Outcomes Based Agreements with sub-insurers, following months of complex negotiations. In the United States, we are actively preparing for the launch of ROCTAVIAN and are working with multiple key treatment centers to prepare for potential approval in June. Total revenue growth is tracking to plan, as supported by VOXZOGO accessibility to more families seeking treatment, our solid enzyme franchise, potential U.S. approval of ROCTAVIAN on the horizon and good progress on the commercial launch of ROCTAVIAN in Europe. 2023 is off to a great start and we are optimistic about the outlook ahead.&#8221;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Highlights&#58;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Total Revenues</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the first quarter of 2023 were $596.4 million, an increase of 15% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to the following&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher VOXZOGO commercial sales due to continued global market expansion and rapid patient uptake following regulatory approvals in late 2021 and early 2022, and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher ALDURAZYME product revenues primarily due to the timing of order fulfillment to Sanofi. BioMarin ALDURAZYME revenues are driven by the timing of when the product is released and control is transferred to Sanofi.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">GAAP Net Income </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased to $50.9 million for the first quarter of 2023 compared to $120.8 million for the same period in 2022. The decreased net income was primarily due to the absence of the $89.0 million gain, net of tax, recognized in the first quarter of 2022 upon the sale to a third party of the PRV the Company received in connection with FDA approval of VOXZOGO partially offset by an increase in gross profit.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Non-GAAP Income</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased to $115.8 million for the first quarter of 2023 compared to Non-GAAP Income of $98.8 million for the same period in 2022 driven by higher gross profit due to increased sales volume partially offset by increased selling, general and administrative (SG&#38;A) expenses to support the anticipated commercial launch of ROCTAVIAN, employee-related costs and other strategic initiatives. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Product Approvals and Launches (VOXZOGO and ROCTAVIAN)</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of the end of March 2023, approximately 1,500 children with achondroplasia were being treated with VOXZOGO across 35 active markets. In the first quarter, VOXZOGO growth accelerated in Japan and Brazil, followed by other markets, respectively. Based on these trends, today BioMarin updated full-year 2023 VOXZOGO guidance to between $380 million and $430 million. VOXZOGO is currently approved for the treatment of children 2 years old and older in Europe, for children 5 years old and older in the U.S., and approved for all ages from birth in Japan. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In Europe, BioMarin is making progress in Germany, France and Italy to facilitate access to ROCTAVIAN. In Germany, 18 people with severe hemophilia A have completed antibody testing to determine their seroprevalence to AAV5. On reimbursement in Germany, BioMarin is now working directly with the National </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Association of Statuary Health Insurance Funds (GKV) to finalize access to ROCTAVIAN, due to the complexity to reach final terms on the remaining Outcomes Based Agreements (OBAs) with sub-insurers. GKV is the primary provider of public health insurance, supplying coverage to approximately 90% of the German population. At present, people in Germany with severe hemophilia A, who are eligible for treatment with ROCTAVIAN, can access treatment through either Named Patient authorizations or previously secured OBAs. In France and Italy, BioMarin is working directly with the single public insurance funds in each country to secure reimbursement and access to ROCTAVIAN, which is expected later in 2023.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March, the FDA extended review of the Biologics License Application (BLA) for ROCTAVIAN gene therapy for adults with severe hemophilia A. The FDA determined that the submission in the first quarter of the three-year data analysis from the ongoing Phase 3 GENEr8-1 study, as requested by the FDA, constituted a Major Amendment due to the substantial amount of additional data and set a new PDUFA Target Action Date of June 30, 2023. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on the updated PDUFA target action date in the U.S., as well as the transition to working directly with GKV, BioMarin today lowered full-year 2023 ROCTAVIAN guidance to between $50 million and $150 million. This updated ROCTAVIAN estimated revenue range assumes contributions from Europe, the U.S., and other markets, including Named Patient authorizations, in 2023.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mid-stage Product Life Cycle Expansion Opportunities (VOXZOGO and ROCTAVIAN)</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the coming months in the U.S. and Europe, the Company expects to learn the outcome of its request to expand VOXZOGO access to younger age groups, based on favorable results from a Phase 2 study in infants and young children. If age expansions are accepted, more than 1,000 additional children will be eligible for VOXZOGO treatment in the U.S. and Europe. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BioMarin is engaged in discussions with health authorities concerning the opportunity to leverage VOXZOGO, a natural regulator of bone growth, in other conditions characterized by impaired bone growth.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product expansion opportunities with ROCTAVIAN continue, including a clinical study investigating ROCTAVIAN treatment in those with active or prior inhibitors and continued exploration of methods of administering ROCTAVIAN in people with pre-existing antibodies against AAV5.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earlier-stage Development Portfolio (BMN 255, BMN 331, BMN 351, BMN 349, BMN 293 (DiNA-001))</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BioMarin plans to showcase progress across its earlier-stage development pipeline at R&#38;D Day in New York City on September 12, 2023. Invitations to the event will be circulated in June.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BMN 255 for hyperoxaluria in chronic liver disease&#58; The Company has concluded the multi-ascending dose study with BMN 255 in healthy human volunteers. In January 2023, BioMarin shared early data that demonstrated a rapid and potent increase in plasma glycolate following treatment with BMN 255. Oral daily dosing at all tested levels for 14 days was safe and showed sustained elevations of plasma glycolate, which is predicted to have a profound reduction in oxalate excretion in patients. BioMarin now plans to initiate and enroll an expanded study in patients with chronic liver disease and hyperoxaluria in 2023. The Company believes the availability of a potent, orally bioavailable, small molecule like BMN 255 may be able to significantly reduce disease and treatment burden in a patient population with significant unmet need.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BMN 331 gene therapy product candidate for Hereditary Angioedema (HAE)&#58; Dosing continues in the Phase 1&#47;2 HAERMONY study to evaluate BMN 331, an investigational AAV5-mediated gene therapy for people living with HAE. In January 2023, BioMarin shared that the first participant treated with the 6e13vg&#47;kg dose demonstrated C1-Inhibitor levels that were approaching the therapeutically relevant range. In March, the second sentinel participant was safely dosed at 6e13vg&#47;kg. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BMN 351 for Duchenne Muscular Dystrophy (DMD)&#58; Investigational New Drug application (IND)-enabling studies continue with BMN 351, an antisense oligonucleotide therapy for individuals with exon 51-skip-amenable DMD. BMN 351 was developed using familiar chemistry and superior biology, by targeting a novel, splice enhancer site demonstrating improved binding affinity and tolerability in preclinical models. Preclinical data suggest that restored expression of near-full-length dystrophin protein at levels of up to 40% will convert phenotypes from rapid loss to durable preservation of strength and ambulation. BioMarin is working towards initiating clinical studies with BMN 351 in 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BMN 349 for alpha-1 antitrypsin deficiency&#58; Preclinical studies have demonstrated that BMN 349 is an orally bioavailable, small molecule that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferentially sequesters mutant protein, preventing polymerization in liver cells that drive the progressive liver disease form of the illness.</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In preclinical studies BMN 349 is titratable to effect, with rapid onset and high potency. Preclinical results have strong implications for potential improvement of current management, particularly for severe liver disease requiring rapid action. IND enabling studies are underway and BioMarin&#8217;s goal is to submit an IND for BMN 349 in the second half of 2023.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BMN 293 (formerly DiNA-001) for MYBPC3 hypertrophic cardiomyopathy (HCM)&#58; Preclinical studies are underway with BMN 293 following a collaboration announced in 2020 with DiNAQOR, a platform company that develops organ specific delivery of novel gene therapies to treat rare genetic cardiac and renal diseases. Mutations in the MYBPC3 gene are the most common cause of inherited HCM. Early investigations suggest that gene therapy-mediated gene transfer can lead to widespread expression of the gene product, cardiac myosin-binding protein C (MyBP-C), in cardiac tissue, which can normalize cardiac hypertrophy, improve relaxation kinetics and potentially alleviate functional deficits in individuals suffering from cardiomyopathy. BioMarin&#8217;s goal is to </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an IND for BMN 293 in the second half of 2023.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">2023 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated)</font></div><div style="margin-bottom:12pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Guidance</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Updated April 26, 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,375</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,500</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enzyme Product Revenues</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,700</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,850</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROCTAVIAN Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOXZOGO Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$330</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$380</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$380</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$430</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit %</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D % of Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&#38;A % of Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Net Income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$155</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$205</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Diluted EPS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.78</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.03</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$360</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$410</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Diluted EPS</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.05</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td></tr></table></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Enzyme-based Products include ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ and VIMIZIM. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full-year 2023 ROCTAVIAN revenue guidance range, provided above, represents global revenue estimates and assumes a U.S. approval in June 2023.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin will host a conference call and webcast to discuss first quarter 2023 financial results today, Wednesday, April&#160;26, 2023 at 4&#58;30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at&#160;www.biomarin.com.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#47;Canada Dial-in Number&#58; 800-831-4163</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Replay Dial-in Number&#58; 800-645-7964</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Dial-in Number&#58; 213-992-4616</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Replay International Dial-in Number&#58; 757-849-6722</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No Conference ID</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conference ID&#58; 9184#</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About BioMarin</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.</font></div><div style="margin-bottom:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about&#58; the expectations of Total Revenues, Net Product Revenues, Enzyme Product Revenues, Gross Profit, Research and Development Expense (R&#38;D), Selling, General and Administrative Expense (SG&#38;A), GAAP Net Income, Non-GAAP Income, GAAP Diluted EPS and Non-GAAP Diluted EPS for the full-year 2023&#59; cash flows from operating activities&#59; the timing of orders for commercial products&#59; the timing of BioMarin&#8217;s clinical development and commercial prospects, including announcements of data from clinical studies and trials&#59; the clinical development and commercialization of BioMarin&#8217;s product candidates and commercial products, including (i) the outcome of BioMarin&#8217;s BLA resubmission for ROCTAVIAN to the FDA, (ii) the potential to leverage VOXZOGO in conditions beyond achondroplasia, (iii) the results from clinical studies regarding product expansion opportunities for ROCTAVIAN, (iv) BioMarin&#8217;s plans to initiate and enroll an expanded study of BMN 255 in 2023, (v) BioMarin&#8217;s expectation to begin clinical studies with BMN 351 in 2023, (vi) BioMarin&#8217;s goal to submit an IND for BMN 349 in the second half of 2023, and (vii) BioMarin&#8217;s goal to submit an IND for BMN 293 in the second half of 2023&#59; the potential approval and commercialization of BioMarin&#8217;s product candidates, including ROCTAVIAN for the treatment of severe hemophilia A in the U.S., and the timing of such approval decisions and product launches, including (i) the anticipated start and growth of commercial sales of VOXZOGO in additional countries, (ii) the duration and outcomes of the FDA&#8217;s review procedure of our BLA resubmission for ROCTAVIAN, (iii) BioMarin&#8217;s expectation that U.S. and EU health authorities take action on its supplemental marketing applications for VOXZOGO in the coming months and the number of additional children that will be eligible for VOXZOGO if such age expansions are accepted and (iv) the level of interest about ROCTAVIAN from physicians and adult severe hemophilia A patients in the EU and U.S., including the number of people in Germany who have completed antibody testing to determine their eligibility for ROCTAVIAN&#59; the expected benefits and availability of BioMarin&#8217;s product candidates&#59; and potential growth opportunities and trends, including that BioMarin expects accelerated growth of VOXZOGO as the product launch continues in future quarters. </font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others&#58; BioMarin&#8217;s success in the commercialization of its commercial products, impacts of macroeconomic and other external factors on BioMarin&#8217;s operations&#59; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials&#59; BioMarin&#8217;s ability to successfully manufacture its commercial products and product candidates&#59; the content and timing of decisions by the FDA, the European Commission and other regulatory authorities concerning each of the described products and product candidates&#59; the market for each of these products&#59; actual sales of BioMarin&#8217;s commercial products&#59; the introduction of generic versions of BioMarin&#8217;s commercial products, in particular generic versions of KUVAN&#59; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption &#34;Risk Factors&#34; in BioMarin's Annual Report on Form 10-K for the year ended December 31, 2022 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BRINEURA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KUVAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NAGLAZYME</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PALYNZIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIMIZIM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VOXZOGO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ROCTAVIAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of BioMarin Pharmaceutical Inc. ALDURAZYME</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of BioMarin&#47;Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="ibaa44edcfad841d6ba0d8cda14256205_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March&#160;31, 2023 and December&#160;31, 2022 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except per share amounts)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:62.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022 &#8317;&#185;&#8318;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580,074&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724,531&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572,017&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567,006&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597,913&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461,316&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">918,921&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894,083&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173,180&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,521&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,842,105&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,751,457&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,635&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333,835&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068,142&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,073,366&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,569&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,510,568&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,505,412&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,057&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,236&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,433,695&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,375,074&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598,231&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572,959&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term contingent consideration</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,925&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598,231&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588,884&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term convertible debt, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,084,006&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083,019&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,415&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,015&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774,652&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,771,918&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#58; 500,000,000 shares authorized&#59; 187,601,106 and 186,250,719 shares issued and outstanding, respectively</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,417,873&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,404,895&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company common stock held by the Nonqualified Deferred Compensation Plan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,949)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,859)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,722)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,867)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(738,347)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(789,199)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,659,043&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,603,156&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,433,695&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,375,074&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;December&#160;31, 2022 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the U.S. Securities and Exchange Commission (SEC) on February&#160;27, 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="ibaa44edcfad841d6ba0d8cda14256205_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 and 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except per share amounts)</font></div><div style="margin-bottom:20pt;text-align:center"><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.247%"><tr><td style="width:1.0%"></td><td style="width:71.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">REVENUES&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net product revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586,426&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505,525&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,834&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596,415&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519,359&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OPERATING EXPENSES&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,549&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,965&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,846&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,836&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,003&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,619&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset amortization and contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,670&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,612&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108,000)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,068&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382,032&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCOME FROM OPERATIONS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,347&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,327&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,820&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,703)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,806)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,830)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,154)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCOME BEFORE INCOME TAXES</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,757&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,187&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,389&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET INCOME</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,852&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,798&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EARNINGS PER SHARE, BASIC</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EARNINGS PER SHARE, DILUTED</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,667&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183,990&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,363&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,886&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="ibaa44edcfad841d6ba0d8cda14256205_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 and 2022 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:66.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,852&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,798&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,421&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,343&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,029&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premium (accretion of discount) on investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,970)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,652&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,695&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108,000)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on equity investment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,650&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,360)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,800&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,615&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,887)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(222)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,796)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,813)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,098)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,001)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,011)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,440&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and other short-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,686)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,143)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,262&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73,932)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,431)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,456)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,817)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities and sales of investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,118&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,818&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220,364)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(147,361)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of nonfinancial assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(310)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,858)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,012)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,782&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercises of awards under equity incentive plans</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,169&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,235&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51,422)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,949)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of contingent consideration</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,475)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of financing leases</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,014)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(566)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,742)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,280)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,457)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,164&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning of period</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724,531&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">End of period</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580,074&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">605,440&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ibaa44edcfad841d6ba0d8cda14256205_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Information</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the Company as GAAP Net Income excluding amortization expense, stock-based compensation expense, contingent consideration expense, and, in certain periods, certain other specified items, as detailed below when applicable. The Company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Diluted EPS, is defined by the Company as Non-GAAP Income divided by Non-GAAP diluted shares outstanding </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities&#58; the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because Non-GAAP Income, Non-GAAP Diluted EPS and Non-GAAP Diluted Shares are important internal measurements for BioMarin, the Company believes that providing this information in conjunction with BioMarin&#8217;s GAAP information enhances investors&#8217; and analysts&#8217; ability to meaningfully compare the Company&#8217;s results from period to period and to its forward-looking guidance, and to identify operating trends in the Company&#8217;s principal business. BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP Income and its components are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the Company&#8217;s results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures&#59; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reconciliation of GAAP Reported Net Income to Non-GAAP Income</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In millions of U.S. dollars)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited) </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.689%"><tr><td style="width:1.0%"></td><td style="width:76.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Reported Net Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense - COS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense - R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense - SG&#38;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of non-financial assets </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and employee termination benefits </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on investment in equity securities </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.8&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.8&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reconciliation of Certain GAAP Reported Information to Non-GAAP Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:76.411%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Diluted EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.27</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.63</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of non-financial assets </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.55)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and employee termination benefits </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on investment in equity securities </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Diluted EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Represents the net gain on the sale in the first quarter of 2022 to a third party of the PRV the Company received from the FDA in connection with the U.S. approval of Voxzogo.</font></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Represents severance and employee termination benefit charge in SG&#38;A related to the Company&#8217;s organizational redesign announced in October 2022. The Company recognized $23.0 million of expense related to severance and employee termination benefits in the second half of 2022.</font></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Represents the impairment loss on investment in non-marketable equity securities recorded in Other expense, net in the first quarter of 2023.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.551%"><tr><td style="width:1.0%"></td><td style="width:75.239%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Weighted-Average Dilutive Shares Outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">194</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">195</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under convertible notes due in 2027</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Weighted-Average Dilutive Shares Outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Common stock issuable under convertible notes due in 2027, were excluded from the computation of GAAP Weighted-Average Dilutive Shares Outstanding as they were anti-dilutive. </font></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:15pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"><tr><td style="width:1.0%"></td><td style="width:32.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Guidance for the Year Ended December 31, 2023 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Income</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted EPS</font></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Net Income and Diluted EPS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">to</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$0.78</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1.03</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and employee termination benefits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on investment in equity securities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of adjustments </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.35)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Income and Diluted EPS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">to</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.80</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.05</font></td></tr></table></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;The adjustments&#47;reconciling items included in this table are presented to facilitate the reconciliation of Non-GAAP Income and Non-GAAP Diluted EPS to their closest GAAP financial metrics, GAAP Net Income and GAAP Diluted EPS. The specific amounts included in each reconciling line item above represent approximations of the underlying adjustments from GAAP Net Income to Non-GAAP Income and from GAAP Diluted EPS to Non-GAAP Diluted EPS. Actual 2023 results for each reconciling line item may be different, in some cases materially, than the amounts listed above as a result of uncertainty regarding, and the potential variability of, those items.</font></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;Certain amounts may not sum or recalculate due to rounding.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;Income tax adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the applicable statutory income tax rate.</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">### </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bmrn-20230426.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0e43f1f0-b255-4e25-b4ed-35f17c544e91,g:b0ec60c5-ba62-45dd-8184-f7166a29b045-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bmrn="http://www.biomarin.com/20230426" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biomarin.com/20230426">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20230426_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20230426_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.biomarin.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bmrn-20230426_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0e43f1f0-b255-4e25-b4ed-35f17c544e91,g:b0ec60c5-ba62-45dd-8184-f7166a29b045-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_aab50738-2263-480d-9c72-5f63bcaf30a6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ccbd2087-cf16-4ceb-b888-6f42d24969ab_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_53ad3fb8-e90c-4664-8349-8446940d0c99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d66e5dec-1622-4e8f-be33-d11e31188c99_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b22d6182-1346-4d2d-9a65-11f48f5eab42_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3ed20be4-93fd-4dd6-91f2-8a816aef8f16_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fc8580ad-329e-407b-88d5-b00ebb2e628d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cdb4e678-0fe3-4bb4-bf1a-94e73b5f8cac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c72aa98b-affb-4462-a538-958f46d7677e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_80e9c20d-fc8f-4792-9074-c6b57de45ee7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d640a674-c3c4-4f4e-9582-d5fa8e1778cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_07fb2d25-3559-4f7d-8f1f-a99542421b64_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4a9f1bb2-9506-4ed6-9a4e-ea58c3abc092_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5aa76dff-b763-4fe3-8d9f-a54d797533c4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c9247250-f89f-4e68-9212-56fdcc25ee9a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_26e837c1-a7d1-4338-a85b-9cc7556b22f2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fd73db40-2719-437a-8e41-3f91012eaf5a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5f9195f8-3d62-425c-a94a-7eafd4d5aaeb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a6039834-d7f6-45c8-9dff-ae73a17f4a44_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e251a5b2-159e-4efb-8c51-96a34b86c0da_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3372bf31-d87f-49e8-901e-8cb843d7b4a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bc0e7aa0-cf81-4cde-bd3c-8d4c3edcfc46_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d5d4bf1c-d69a-45f8-9da2-9fa8cf1a4e20_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bmrn-20230426_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0e43f1f0-b255-4e25-b4ed-35f17c544e91,g:b0ec60c5-ba62-45dd-8184-f7166a29b045-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biomarin.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="bmrn-20230426.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.biomarin.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d3aeb38e-ca3b-44e4-bef5-f4783132bba9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_DocumentType_d3aeb38e-ca3b-44e4-bef5-f4783132bba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_89021b77-ee51-4a35-8320-95033bb0622f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_DocumentPeriodEndDate_89021b77-ee51-4a35-8320-95033bb0622f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_31c3bed3-347e-4f5c-bec2-ffe0e155c178" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityRegistrantName_31c3bed3-347e-4f5c-bec2-ffe0e155c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1a50657d-1c3f-4bb0-8a51-b0c90e6576cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1a50657d-1c3f-4bb0-8a51-b0c90e6576cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c54a05aa-5eb5-4d43-81c8-70caac3471a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityFileNumber_c54a05aa-5eb5-4d43-81c8-70caac3471a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b41d6d80-44f0-48f5-b40d-141a3d4b511d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityTaxIdentificationNumber_b41d6d80-44f0-48f5-b40d-141a3d4b511d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_81cc3a42-825c-4c31-aec5-4bcd31fbe8aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityAddressAddressLine1_81cc3a42-825c-4c31-aec5-4bcd31fbe8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_59985a40-bf9e-49bb-b2f0-8395e6b5c2f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityAddressCityOrTown_59985a40-bf9e-49bb-b2f0-8395e6b5c2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e032d888-64bf-462e-ad80-72b096e470a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityAddressStateOrProvince_e032d888-64bf-462e-ad80-72b096e470a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_40a94338-2911-404e-8094-faca1284a606" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityAddressPostalZipCode_40a94338-2911-404e-8094-faca1284a606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4023c122-fffc-4d3d-b572-9f989463ca0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_CityAreaCode_4023c122-fffc-4d3d-b572-9f989463ca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bf813e09-30ce-4549-97f2-76ffbb41a34f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_LocalPhoneNumber_bf813e09-30ce-4549-97f2-76ffbb41a34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0b17481d-cf28-4eb9-8862-24fc62da0ab3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_WrittenCommunications_0b17481d-cf28-4eb9-8862-24fc62da0ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0025f846-11af-4637-b48b-a5c66c79fdc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_SolicitingMaterial_0025f846-11af-4637-b48b-a5c66c79fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_3d34e3de-3a2b-409b-b5ce-5a8442d5b574" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_PreCommencementTenderOffer_3d34e3de-3a2b-409b-b5ce-5a8442d5b574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d33a6aa6-f820-42f7-b7f7-05ffae963415" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d33a6aa6-f820-42f7-b7f7-05ffae963415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5cfb7321-4329-4b9c-95e1-a7c21585bb20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_Security12bTitle_5cfb7321-4329-4b9c-95e1-a7c21585bb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_da5ff606-f626-42bf-ba52-2cc06a53c922" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_TradingSymbol_da5ff606-f626-42bf-ba52-2cc06a53c922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e1a79447-8866-40b9-8fb7-85767b34de57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_SecurityExchangeName_e1a79447-8866-40b9-8fb7-85767b34de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_78cb1a0b-eef9-4c69-9c58-1befddfb95a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityEmergingGrowthCompany_78cb1a0b-eef9-4c69-9c58-1befddfb95a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b276684d-5bda-417f-8713-5f4f33c5bad1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_AmendmentFlag_b276684d-5bda-417f-8713-5f4f33c5bad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_187e96ae-a761-4183-b558-2ad176c53a5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbb9707d-3b60-40e7-81ec-e3a5073f4568" xlink:to="loc_dei_EntityCentralIndexKey_187e96ae-a761-4183-b558-2ad176c53a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>bmrnlogoa01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bmrnlogoa01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  : + # 2(  A$! Q$!_\0
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M,8J<X4?91Y?=_P#;F=>%]I"53VLN;_ACY8_;&^/&O> O$WA+1O!T4]Y=:/\
M\55K\5JW*Z;$^PH_^R^Y_P#OA:^GO#>O6'BC1=/UG3)5N;#4;>.ZMYEZ-&Z!
MD/Y&OB;X"_''X5ZQK'Q+\<_$'Q5I%GJOC.Y>QCTF]8AK;2HU,443C'5U^_\
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/B)3PLJ3,IT(PQ4:B/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139973548889264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioMarin Pharmaceutical Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0397820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">770 Lindaro Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Rafael<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">505-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001048477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>bmrn-20230426_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmrn-20230426.xsd" xlink:type="simple"/>
    <context id="id433381570bf46f4910d270a56672296_D20230426-20230426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV80L2ZyYWc6MDhkYjVlZmQ2NDc2NDRlMGI0ZjM2YjcxNWY3MWQ4N2YvdGFibGU6NTgwZTNlYzlkODE4NGU2YjliZjc5OGZjY2EyN2JjODcvdGFibGVyYW5nZTo1ODBlM2VjOWQ4MTg0ZTZiOWJmNzk4ZmNjYTI3YmM4N18yLTEtMS0xLTExMzAyMQ_78444f19-7370-4eed-9b61-b3a1b0d98130">0001048477</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV80L2ZyYWc6MDhkYjVlZmQ2NDc2NDRlMGI0ZjM2YjcxNWY3MWQ4N2YvdGFibGU6NTgwZTNlYzlkODE4NGU2YjliZjc5OGZjY2EyN2JjODcvdGFibGVyYW5nZTo1ODBlM2VjOWQ4MTg0ZTZiOWJmNzk4ZmNjYTI3YmM4N181LTEtMS0xLTExMzAyMQ_b8997d0d-1fea-4ab2-ba57-5b4b21a5d104">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV84NA_be8c2567-094e-47b1-92c6-b927a97bd549">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8yMjU_b9edf739-eea2-4658-9de8-3f9807190f9b">2023-04-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNjYy_1cc06ebe-5312-4524-bf2d-daa428507c78">BioMarin Pharmaceutical Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18wLTAtMS0xLTExMzAyMQ_3431473b-e2f9-42c1-a390-0628240c3e4c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18wLTEtMS0xLTExMzAyMQ_907b1d68-d6d4-4789-8369-d2f7110ef2be">000-26727</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18wLTMtMS0xLTExMzAyMQ_98ffb150-e3b4-4c95-8d28-5c0f3aeb7837">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTAtMS0xLTExMzAyMQ_a08e4441-962b-49d0-934a-85a810e44724">770 Lindaro Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTEtMS0xLTExMzAyMQ_2d06f65f-1af1-4475-b695-05afbed5e916">San Rafael</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTItMS0xLTExMzAyMQ_99b98106-5ab5-4bdc-9ce3-fd1f61bdedb3">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6OTg0MjgyZGMzMWUyNGI3OThlMTA4ZjlkZTEwZGQyZjMvdGFibGVyYW5nZTo5ODQyODJkYzMxZTI0Yjc5OGUxMDhmOWRlMTBkZDJmM18zLTMtMS0xLTExMzAyMQ_b315f251-c097-4d5b-83b9-4ab44b69bc98">94901</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNjYz_78973779-9a25-4f25-b3fb-bdc4d0326bc5">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNjYw_e9871956-67f0-4de8-bfdf-6e536b2a156b">505-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV82NzY_98bdd711-3a0d-407b-8231-5cc67ad22caa">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV83NjY_4ff025f4-76a1-489e-95a0-a90e4c6d1a9c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV84NTg_e411a04a-d21b-46ff-9cd3-151846db89c3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV85NjY_5d2ba802-599a-48d4-a5d3-7e7a832acfaa">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6ZGQ5OWRkNTYzNWNhNDIxYWFhNzI0MDdiNmI2MjYxY2MvdGFibGVyYW5nZTpkZDk5ZGQ1NjM1Y2E0MjFhYWE3MjQwN2I2YjYyNjFjY18xLTAtMS0xLTExMzAyMQ_ddf9b64a-72b0-4230-8303-43f0e63bfc64">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6ZGQ5OWRkNTYzNWNhNDIxYWFhNzI0MDdiNmI2MjYxY2MvdGFibGVyYW5nZTpkZDk5ZGQ1NjM1Y2E0MjFhYWE3MjQwN2I2YjYyNjFjY18xLTItMS0xLTExMzAyMQ_2b4d57ad-4518-459c-a10f-4a3069e167cd">BMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGFibGU6ZGQ5OWRkNTYzNWNhNDIxYWFhNzI0MDdiNmI2MjYxY2MvdGFibGVyYW5nZTpkZDk5ZGQ1NjM1Y2E0MjFhYWE3MjQwN2I2YjYyNjFjY18xLTQtMS0xLTExMzAyMQ_48a1cd54-8fa2-4a6b-87a6-651ffc375e7e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="id433381570bf46f4910d270a56672296_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YTA1ZjhhYjJmNTRmY2M4N2Y4ODU5MjcwYmJhN2IxL3NlYzo4OWEwNWY4YWIyZjU0ZmNjODdmODg1OTI3MGJiYTdiMV8xL2ZyYWc6OWNlYTJlODUxMzU0NGVmZDg4N2IzNWU4NmY4ZmE5NmEvdGV4dHJlZ2lvbjo5Y2VhMmU4NTEzNTQ0ZWZkODg3YjM1ZTg2ZjhmYTk2YV8xNDAx_154eb444-bb5a-4a51-bb74-aa6f428ceb32">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #I@)I6+ U[/% $  ">$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)68;6^C1A#'O\J*5E4K)>'!CTEM2XZ3M-%=<FZ<]J16?;&&P5X=['++$L??
MOK/8!E>'!]^;P +S]X^9V?\N&6V4_I*O 0Q[3Q.9CYVU,=F-Z^;A&E*>7ZD,
M)-Z)E4ZYP:%>N7FF@4=E4)JX@>?UW90+Z4Q&Y;6YGHQ481(A8:Y97J0IU]M;
M2-1F[/C.X<*+6*V-O>!.1AE?P0+,G]E<X\BM5"*1@LR%DDQ#/':F_LUMT+4!
MY1-_"=CD1^?,OLI2J2]V\!B-'<\200*AL1(<#V\P@R2Q2LCQ=2_J5+]I X_/
M#^H/Y<OCRRQY#C.5?!:168^=H<,BB'F1F!>U^1WV+]2S>J%*\O(OV^R>[78=
M%A:Y4>D^& E2(7='_KY/Q%% QS\1$.P#@I)[]T,EY1TW?#+2:L.T?1K5[$GY
MJF4TP@EIJ[(P&N\*C#.3.Q46F&3#N(S8O33";-FCW%7;9NUP?^0:_#4;XX9[
MY=N=<G!">9KI*Q;T+UC@!9W_A[L(69$&%6E0ZG5.Z,W4&VCVSW29&XVU_+>)
M:*?0;5:P#7Z39SR$L8,=G(-^ V?RTP]^W_N5X.M4?!U*O<[DZS:#)C@Z?'CY
M@8#H5A#=\R#FH(6R%8T8]D4C#ZU4E:^M?KT*K4<*[IOK!5;"5A 9GWG:"$;K
MW KUQ+60;+[FV*4A%$:$/,&N#:\(S'Z%V3\'$]64SI0N9\$%6QA,(E.:S50A
MC=[B,6IDI\7O[@G"044X.(?P023 GHMT";H)A-;P/.\RZ ^" <$SK'B&Y_"\
M\G?V&&'OB1CK49K':3I:L3^\]#K7@V'@$7C7%=[U.7C3*,(YGU\<3MA'?(Y]
MDHU5I!4' \]&1UPK; R-UDM@^E[MQ-YW@<[L"%ON56UDH_W2<@LNV0N/.204
MW=$ZX7\7734CYEJ]"1DVYK%%<S:ET.J%P2=]_1NTN<H-&L+?(CLY35L4K[O7
MGD^QU8N"3]MZ6<0I[I=.H] "7;]'@=0+@T_[^4=E37*^5I)RC1:1GM>[[ \\
M:EKZ]7K@TT;^60MC0&)BTK20>\_(&ZEHH9@G.5!(M??[M#\O5")"881<L2=L
M;RUXTLA#J[3RU$[OTS8]UW 98GH Y]=N;P$RPEW0IS@^43]:KY6L]GR?MNAO
MR![SO$"R5D!:MA6P=GV?-NE787!]5#'S@Y^7O[ %A 7VV[:1B5:R_8F+V<*H
M\,L%R[AF;SPI@/WH77FD2P2U]0>T5[]J'MFF6VS3I6ILN1:!VZ>79XJDMOF
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" #I@)I6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #I@)I6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( .F FE8YX] E[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .F FE:97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MZ8":5BP->SQ0!   GA   !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .F FE:?H!OPL0(  .(,   -
M          "  90,  !X;"]S='EL97,N>&UL4$L! A0#%     @ Z8":5I>*
MNQS     $P(   L              ( !< \  %]R96QS+RYR96QS4$L! A0#
M%     @ Z8":5APX9>H_ 0  / (   \              ( !61   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( .F FE8D'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( .F FE9ED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bmrn-20230426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomarin.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="bmrn-20230426.htm">bmrn-20230426.htm</File>
    <File>bmrn-20230426.xsd</File>
    <File>bmrn-20230426_lab.xml</File>
    <File>bmrn-20230426_pre.xml</File>
    <File>earningsrelease-26apr23ex9.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bmrn-20230426.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "bmrn-20230426.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bmrn-20230426_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmrn-20230426_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bmrn-20230426.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "bmrn",
   "nsuri": "http://www.biomarin.com/20230426",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20230426.htm",
      "contextRef": "id433381570bf46f4910d270a56672296_D20230426-20230426",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.biomarin.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20230426.htm",
      "contextRef": "id433381570bf46f4910d270a56672296_D20230426-20230426",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001048477-23-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001048477-23-000016-xbrl.zip
M4$L#!!0    ( .F FE;RMF&AHQ0  'J!   1    8FUR;BTR,#(S,#0R-BYH
M=&WM/6MWVKBVW\^OT&7N/2==*P++EE^TY:Q,H#ET"K0);0Y\Z9(M&4P,9FR3
M0'[]W9)-0@))2)JDZ4RZ5EMLO;:V]EM;\KM_S\<1.A5)&L:3]R52UDKHW[5W
M_X/Q?W\__(3JL3\;BTF&]A/!,L'169@-T3$7Z0D*DGB,CN/D)#QE&*LV^_%T
MD82#889T33>N%29535 C((&&/=TT,16ZB3TJ.#;,@-B^2:EPR>Z@ZFG"MS0?
M"IFE8VIRCAWB4!S8Q+*8[GH:-7=YU7&99@8.\_3 I('O.W;@.*:KVYKG,=LC
M<MAA!K.#&4[2*A?A^](PRZ;52F7N)5$Y%7YY$)]6H* "X.JEHN(\O:QX=G96
M/C/*<3* *AJI_+?UZ<@?BC'#X23-V,07RU91.#FYTDR-430T*K+88^E%]7">
M;:X=3J"JD,BO9 F;I$&<C%D&BR-AU+"F8Z)?=G+3B,18Z>AB8FLP%E,CKNM6
M5.D*>!CP<Z7R$E^W04A,K#G8($4_-P\F%^8"+H [O 5W5U!=C=AD\+XD)OCK
M40D66#!>>S<6&4.R/19_SL+3]Z7]>)(!V>+N8@K-_/SI?2D3\ZRBAJ[4_O&/
M?[S+PBP2-6^<3+ D6(WJUKM*_O)=)>_:B_FB]HZ'IRC-%I%X7^)A.HW8HCJ)
M)P( ".=565$D^<^0<S%1/Z&\#;R3A'X^_CP[%,'[4LBI81@.,8%, VH%U"4:
M!YIEIF79NNY:W^M+4"Y@*J$)&\NA15AM3 "^Q3Y,)V%1<\+%_ ^Q**&0RZZ-
M;PNO'I]^T@]/>T9KQD>-T_Z!.^J,!F:ONT?ZH^&P-_HX;G</QSV]1=MZCW;J
M7\W6R#_KC3\.VWIS_LEH1[WSF':.&V?MXQ[M'3<7_=%7K3]NCSIU/N[4!Z33
M;1JM@X]AK\O#UC='^Z3W%[UCWVK5AR>]T;>H/_ZBM^L^_#V,6@=-K3]JZ;V1
M/X?^C-;Q%SGN*3_X$'H'7ZUV=W#6[\HQHY-.O4';!U^A;A3V1[[9.>B/>GIC
MT=8_PMA^T>8;C&5.^MV8=.J_1RW]VZ@#?;:Z ZW?[8>=8YC?^0F5\/8 SMX8
MYDF<Q:=N(VL=:7/X?]XZWUNTOGRW'4II0%QL&[8&X@@DD>M9!'L&(Y[&78<8
M6JFF =]KU*&V_:YR95F?<I7W0.AR*7@_1&SPNKIWK2[9L+J>X[HVUS@F@6"8
M@IH ?6+:V/2HIQ-F<EC54BU@42K6%K9RE943$8A$@ 1*-T@@*3:KJ5(*L/1(
MB=%J!G+G?2D-Q]-(BBWU;IA(RK@B;,KSE$,7E:M]Y.-?#EK D,:S1#TI>5DM
MR*V@C0>0V[(CH23*\BGD\CD(18(40&*C#MAO_G&5,ZXWKBU?7>U]"OB-^?()
MQ'J2U<&NJ$F@L$:QE+_7RR[ Y#=4798LGY>#5*X@:HG5"S165D1W!01\+N45
M.N\R+;Z3TFJ;0C.,PPD>"FG^5*E>MLUI]O8LY-FP2C3M_TJJ:NU=.F5 5%Y2
M@0[RWWD_:[U)F#&+PL&DZ@,210(]9,R+Q+*"%R< ._;C*&+35%27/]XN-52N
MJ+%J]';,D@' Y\59%H^K$C8P^K+09U$QB!HO+[X$NZSEH&> HXPO1RZ*RZJH
MDO'U,M<IN]K-Q5J97)155-_)LD*!0 "PI-K!K"2:WI>,TK6)%U/1IQE*XRCD
MZ#=-_7D[99R'DT%50T3U<CE,1>%B2V3+89?E $6<5)<#!$!1.&#C,%I4_[67
MA"SZUVX*EA"83$D8Y,5I>"ZJA *>U>-9/BT;6JM%*:9); J(^-IN=AMU=-3=
MZS:.KI+%2X!1EPMYU-C_>MCL-AM':*]=1XW_[O]GKWW00/N=5JMY=-3LM)\=
M<.TNP*E$[C%+AT -63S91?7R?AE<$Y.ZSPZLM16P'SJ'+?2$=L72G\OMXI]I
M5LR79D7G&-IV/T;0)ZCNKUK[X-NX7Q_ .,WS]O%7VA[W0-TWS/:X 2;"-\K_
M\S'JZ]&I-XK-GOYMV!I#G6[CO-W]HO6/^V!F#(S>J$7ZW8$.L(][W1.]]\VA
M[;WOGG!\W;1LK+E48"I]1%?W+>R!9&>N[7$@C%+-P7]<-PC0C>12B-4LGE8)
M2)NE[,&1"&!--6?E59*OLWJW)97I!@GT>U"9NQ4K R,?-MI==-CXW#GL;C6U
MGPWRYUF2SM@D0UF,CH0OO4U$#-0Y1,3<X6]0'*#N4,BB61)F(1AJC;D_!#M-
MH#T_D\7$->B]F7Z3HGYZ6;$=2J3)(R=V**9QDJ&=Y;-@8/2(-$/B5 9N$E4L
M^)OJ<\B5S\KT:N0&60GEH0'H?IY5.;S!8QAS*)MASA9X ;!B,?E[":)%:_3U
MN^<*'MB&BX5@.J:6Z6"7"P<;@>MH-G&UP/5*M;UI$D;__(U8VEO=VE4QM757
M):?-QU!1^E9T=[,L?" 7K<@9?7LY\_@*6,WNR2,WAV(0IC)NEK6AY.]%^G-P
MVA??B>]KEO $-@TBP[LZQ5Z@<Y (C.J.J=F^[91JOX=QBR7A!'T>,A BOI@I
M9P4U)WYY>_7\1,3D;&7,[33F#)2/I  IF).+E4<L1>E4^-)3Y@CF&&8I G4%
M<CIYLYS++^/KZ6[9IO96OMY]NB6D;%OFHW<+CJGS^,!26C:LAW5[>YEIT/MX
MT3>YS$N76)_.T35C3EJJU^DC)XW2)C%=$-6:K:N7=7/-V"U>_BP[27L6B0X2
M*4[ R%)[($<9F#G[\6R2)8O]F%^U@>26B@QL96*:Q*>RGU_4^,F#NYWN0&N-
M!HO^0>N\=?QUT3YH&IWN,&IU]VA_%)WTNXVS_L$7@*%U/;AK=NI?%IWZQY/>
M>6O>[S:UG@H(P]CUX;AS? A]_'[2KW\<MXAS]JF[=SVX:U"#4-OPL- #%U/=
M)Y@9KH8U2W=TJOF&H#Z8R")B9RS9$-^]$GDK>.N";:QMV"8GY!L9YZ]#WA_"
M2$#O'G#M*ZG>3:IK^Q"N9GN$6P[F%J>8VHZ+'<-R,=<#FQ!-!+HG5"P=Z[ J
MZYM,2UI]$)4^DG G9>4<7(MDY"__VL*]R^;-8E/#5P+^E16V9H76&BLX0> 1
M4\/"\( 5?-?$#M<=;/I:8##AV8YAEVK *IKAVHZN;2&W']?N 1_TI1L]]E9\
ML:/L$!0G*,Z&(D&C61*F/,P#9^"+A*LVBZJ6#-@D/%?/;YY./^8(?CXT[,?C
M<9C*W"8D]1C*N??-C4+UE7)VFN7#\E$9-<;3*%X Z5P5?Z@=E^^BCW4DKN_$
MK6WX&6L;?NMD=J6;U:KN5B.^.D?/KS_W.$]$FA;_?0( R*ONO$MWGF_P>)CF
M"$HIP:ZE>YBZ7,.N01EV3.: %4FIK=-2S;8U!$CF+(G1498(D=W3]WE.KOC[
M6I4%.^S#ST[2C<]>HP#;\,2::Z5SS0HL,\"$!00#"YC8L\"HU$P6>(*;PB56
MJ78$5'/( B:B5UYXN;R@#-9.\CF)3T.5Z_L:-_MQCFFN>6"NYX*ZL+#)/!-3
MC_O8]86! TX"BWA<<,\HU?:!V #]DY"]8([YV]M4GV-@B:@?3O,X\RL[W,D.
M:P$)SR!FH)L$^YIK8\I-#SN&Y\IL84I!E7B^ZY1J+G4U\L.<\+?W2+;T/POJ
MEE&*SPFH@G#*(M28"W^6A:<"=0)P145Z_QC%C<[C*]HEVD&.("E('L.Y?^XT
MVSOE<KX=_X2"65KR>XE@OZPH_J&<CO/OMN/:AFV[V&4ZV!6!/-EG!!X& X-R
MS= MSS=+-4K,ZV+TS5-FI7V*@5D_#^/)K[R!]4,K<_9=N(Y-7-/"EAUHH.*$
M@[V !]@2IF%Y.B.FY95JIF9"!6TMXO[R,FN(DE:7653_2E$F(C&5JXPF:IEW
M97@[FDGAA!@P)=#4FEQ;F<D5 6V6K74_K'CYP/RV'^[_6=))VW&&]J;3"/2;
MS#MZMMG<-U_X3@)1L]GY -ZC2(K<JT0YD_#(<ML"""1 >7HP1ZET-U'$TF6N
M[/7X]JW'=BX*'_LP ]V<NCT4_@G*A@*Q*?C"4^@Q$\B+Y\@347PFYR4+Y>R1
M@_] 01A)+@A38(E,3,"_DQG4:3B>11F;B'B61@N4LBQ,@X5J632(/5@XMMPM
MD@4KV6LSZ =P.5DLRX(X@L%E.^F?AW*[)44[J1#H0$Q$HK+VH.TLWW[:*^OE
M'-PWU?MA^L>-K"<Z>;)YL9Y0LQTG80;K*;>W9I-B:R9=CYEX<1QY#!8G Q+Y
M>VD_O7W>^^XZ'N<V(=A@&L=4L\&_ X&#3=^W;,9UW6>L5/OG;ZY-Z=LUW5<@
M&19N%<MHNG(6X7 &LI+J9L$3V=4S"/+HP0ZQT?Z'0P1K6(:*-ZNA'R;J5Z:Y
M@VF.8M!NL#*300NDI@3UE6-6.,8 >_$[#0)--P.*;8L13!U78-=D&F:N)JAO
M<<)<_V:.N>4TPGWU_);D<KFF:%PLZCJ#$LHPT5=X],KAH L.I5HYK_EFW?QY
M9;&M6.QS(J1.DL?6U3%#:7(DG2"0OM<KJZT<1NP.O@M*"-. X+A./ S(#K#K
M<P,3DSC4XI[C^L9+8C586^RO+.Z=>I%0CO4=[\UVC)?7?66]1V*]9IK.1/+*
M@)L9T)2ZSN2ZQQQ-QZ;K,M!UG&)F @/:PF:.H3,_N,4Z?'[^0_=G0$-@NN-O
MQX!%W?LRX'-RSXIIG;NC(@&'=KKI;+"2.X5["E.MHI]SK,JURYIM/>14%;@+
MFKW=V9_[E5%-?_3C3X9>UHR'=?L3@#7*AGNONTD>L%_T],=#MMO7Z<K+S/)C
MX?X0^1%+TWLDO_[8GMF+P4'"5"SX:#'VXF@GO4_Z[U\# ^WB"*HB K%4 2 G
MSX8AO+D4IE<P<P?U%\*SN!]BY0Z>MR\*(VNJY*F3- HMM2"ZI[COE[2L\M2,
M_L$7LW-\>-+N]J!.>]BN-^>]XP_#]GE3:]5YV!XW]=:H-P=XKZ5F3$_Z]1,3
MVI,V6%\]O:&U1A^&O>.&T1I].8,Q]=ZHMVB//HQZ!&!<SW?E/' ]"[PC6_<T
M3 '-V#$T U,CT(1E>(%OT5)-6KQ QD=9[)_LHBE+T"F+9@+]KSS-?'/.QJ/P
M_2O];Z;_0MSFTO:5^+<@_K4T/=VCW+09Q]0D#OSC^I@1+<"4&9KE"F+9/B_5
M?F\=ME])_&>*^*4WE5_E<=V_EHKVET]6?3XN^'*="ZC#B,]-BIU 7I+#+ \[
M-K.P99(@\ W;%+8 ZPX\O#9+.?L3'42QQR)P B-P U&+)2>WG'^X.5OIQ?B[
MS0F7SKU W@+Y:N<77- 3,-J$.M1W;5LV3!$ )F": VGM#I+X+!O*&,%4;M6R
M%'$1P!#JPI%\WTHSER[RM4VK_+XL ^W(RX?LMVKO:EDY5%>53.55)7)G/0\T
MZ![6-_2UZ1*NBTYET.&RW4JWY4>(0#Q1#*9Q W8?\QJFGQY)S+.,EU,]4#/=
MSR?Z&D2\DF!5WYM_)R85'J44>YXI[QDV"?RR*68,,*\[OO ,_25%$5]N>*\9
MW"+ 9%+71FD8KN6G#$'6*14 LFX2J[C@+!6J%K!(D04C;ZX/5:PPORY8$K8:
M*UK(P=5W#B1G3\29%'.). U3: <2E$U\N<O(?%]>\R(KR^OI.4MXFN>_\)N"
MDL8.NPA*KHK&,KH@CX?L?:S87FICXUEW-.(;P;IV%?(TSO%=343$9"KWVN7(
MEU:G"K!JETV8!Z;G+%MO<M=]RO>]U]F^N-=YF%S:RP.!O42P$\P"T$]5%IVQ
M15JJ/,'ES\^8\-?,Q!CI94U'AR*=19G*N.\ ,Q2["4#2Z,,%M>_'P'VRX)[*
M^0J- @>#;U UK,?:=;L^T\TDVIF@#3<I[J+;KIA#.Y))"ZWW!I Q 6;WKPB
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M@#S/K_A*_GI^0B7_F+SZ GWM_P%02P,$%     @ Z8":5AW\"EF  @  SP<
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M"$EB+B6@B?X)AUX QSQ5(V6$>)(F4:BFSIUIVXP\.MRT..^&7(E3"]8:7G6
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M,#(S,#0R-E]P<F4N>&ULU9K;;MQ&$H;O_12SL[?;FCZS*5@*M(J]$*+$@JW
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MF#NCX>WJF8BG>.#PS?V)_J7_K_WAF_\!4$L#!!0    ( .F FE8>.Q]25DT
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M^S.8>!*^(\^W_XHUP"%Z%%)RCA] ;!0^2=9EH 4@G$<^\'=5RB4;CW2 6^
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M !TQ'P"4+V8 :J(LCR&=/A2.?"\:CIBP29I?@MIOL:O8,<BCD&(V<98.AJ:
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M/J8)P5SY<J8FHQ.>Q9HK7M\G:I<WS3AFT@B\FH67#!!/(\HV]%'T.-YPJE#
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MH+H$M9^,[ ZHY47+':W._EG.OFTHW6;E3WS*)2A9*'M(+8X\-["MN +R ;E
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M#D)>?F+G_WN%(<N#,_>KV_//292G7A!BJ#7@C@A8Z=&HA.J6T5*:C4I_W1Y
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M5\ZS9_+L90=UO#W\\N7+U;?[CX7,]=5D_J;O65/X9Q2.G??_/U!+ 0(4 Q0
M   ( .F FE;RMF&AHQ0  'J!   1              "  0    !B;7)N+3(P
M,C,P-#(V+FAT;5!+ 0(4 Q0    ( .F FE8=_ I9@ (  ,\'   1
M      "  =(4  !B;7)N+3(P,C,P-#(V+GAS9%!+ 0(4 Q0    ( .F FE9-
M$J%";PH  $1>   5              "  8$7  !B;7)N+3(P,C,P-#(V7VQA
M8BYX;6Q02P$"% ,4    " #I@)I6XG;.7+<&   Y,0  %0
M@ $C(@  8FUR;BTR,#(S,#0R-E]P<F4N>&UL4$L! A0#%     @ Z8":5AX[
M'U)630  5_H# !X              ( !#2D  &5A<FYI;F=S<F5L96%S92TR
C-F%P<C(S97@Y+FAT;5!+!08     !0 % % !  "?=@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
